NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

PARADIGM BIOPHARMACEUTICALS LIMITED.. (PAR)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of PAR: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000PAR5
Address: Level 2, 517 Flinders Lane, MELBOURNE, VIC, AUSTRALIA, 3000
Tel:  (03) 9629 5566

Date first listed: 19/08/2015

Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ

News & Events

Expand this box to read and print

The suspension of trading in the options of Paradigm Biopharmaceuticals Limited will be lifted immediately.

28/11/2023

The options of Paradigm Biopharmaceuticals Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Tuesday, 28 November 2023. The suspension only applies to PAR's options and does not apply to any other quoted securities of PAR.

21/11/2023

The suspension of trading in the securities of Paradigm Biopharmaceutics Limited will be lifted immediately, following the release by PAR of an announcement regarding the completion of a capital raising.

08/04/2020

Bids received significantly exceeded the size of the placement. PAR fully funded to Phase 3 OA trial completion and readout. Support from large Australian and International institutional investors. Significant endorsement of PAR and its treatment of OA. Capital raising enables PAR to be focused on the clear path to regulatory approval and commercialisation.

08/04/2020

The company releases a notice of Proposed issue of Securities - PAR.

08/04/2020

The company will host a conference call at 8:30am (AEST) Wednesday 8th April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials. Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7th April, with the company collating questions sent and will endeavour to answer the most frequently asked. Questions are to be submitted to investorrelations@paradigmbiopharma.com.

07/04/2020

Paradigm reports very encouraging real-world data ahead of its phase 3 OA clinical trial using the Phase 3 product and two Phase 3 endpoints.

06/04/2020

The company receives clarity on US regulatory pathway. The pre-IND meeting was both positive and informative for Paradigm. The positive outcomes from the meeting were clear guidance around the primary and secondary endpoints for the Phase 3 clinical trial, the number of Phase 3 studies required for registration and overall clarity and guidance over the requirements for the Phase 3 clinical trial design and NDA submission.

06/04/2020

The company releases its latest Corporate Presentation.

06/04/2020

The securities of Paradigm Biopharmaceuticals Limited will be suspended from quotation immediately under Listing Rules 17.2, at the request of PAR, pending the release of an announcement regarding the proposed capital raising.

06/04/2020

listed entity carried for record purposes only

19/08/2015

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    18/05/2023Helen Fisher10,204$0.982$10,020
    12/05/2023Paul Rennie73,851$1.029$76,001
    19/12/2022Paul Rennie47,720$1.289$61,521
    08/03/2022Paul Rennie48,167$1.051$50,634
    11/05/2020John Gaffney-115,695$2.369$274,118

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Paul RennieNon Exec Chairman, Managing Director19/08/2015
    Jeannie JoughinCOO03/06/2020
    Abby NivenCFO03/03/2023
    Amos MeltzerIndependent Director08/12/2020
    Matthew FryNon Exec Director04/03/2024
    Donna SkerrettExecutive Director, Interim CEO03/07/2020
    Abby MacnishCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Helen FisherNon Exec Director11/02/202104/03/2024
    John GaffneyNon Exec Director19/08/201520/10/2023
    Justin CahillCFO13/10/202003/03/2023
    Marco PolizziCEO01/07/202220/02/2023
    Chris FullertonNon Exec Director19/08/201520/11/2020
    Kevin HollingsworthCFO19/08/201513/10/2020
    Graeme KaufmanNon Exec Chairman19/08/201524/06/2020

    Date of first appointment, title may have changed.